Another Case for Buying Options: Gilead’s Purchase of Pharmassett

Here's another case for why buying options is better use of your capital than stocks - there's more bang for your buck as they say. Jon Najarian of CNBC's Fast Money tweeted this gem about Gilead Sciences' purchase of Pharmasset for close to $11 billion. If you owned the stock you got an 85% return. If you owned the options on the stock you were up 3,300% after today's news. Wow! Pharmassett has the stock ticker VRUS. Update: Turns out some of these Pharmassett option buys might just be too good to be true. Meaning, these options buyers knew

Continue reading...

Tagged gilead, jon najarian, options, pharmassett